Drug major Cipla NSE 0.65 % on Wednesday said it has received final approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and emphysema, in the US market.
The approved product is a generic version of Sunovion Pharmaceuticals Inc’s Brovana.
The company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla said in a regulatory filing.
Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Quoting IQVIA (IMS Health) data, Cipla said Brovana had US sales of approximately USD 438 million for the 12-month period ending April 2021 according to the reports published in economictimes.indiatimes.com.
The product is available for shipping immediately, it added.
India, December 03, 2024: SCINQ Neurocosmetics, a pioneering skincare brand, has launched in India, bringing a transformative…
The company has its presence across Delhi NCR and in Kolkata New Delhi, December 03,…
By Dr. Priyanka Kuri, Consultant – Dermatology, Aster Whitefield Hospital, Bengaluru As the seasons change,…
New Delhi, December 02, 2024: Officenet is a leading HR tech firm known for its…
Hyderabad, November 30, 2024: Shaping new realities in the premium supplements market, RediClinic is quickly…
Maria Juan from wins INR 2 Crores at the award ceremony in Bengaluru, selected from…